Tevimbra by BeiGene for Gallbladder Cancer: Likelihood of Approval

Tevimbra is under clinical development by BeiGene and currently in Phase II for Gallbladder Cancer.

Neurocrine reports a second PhIII success in congenital adrenal hyperplasia, this time in children

Neurocrine Biosciences said its treatment for congenital adrenal hyperplasia (CAH) — a genetic disorder that causes hormone imbalance — helped reduce the daily dose of

October 6, 2023

AbbVie purchases neuroscience developer Cerevel for $8.7 billion

Abbvie announced Wednesday that it will purchase Cerevel Therapeutics and its pipeline of experimental neurological and psychiatric medications for $8.7 billion. The deal marks the

December 6, 2023

Transcarent, Glen Tullman’s health tech unicorn, raises $126 million

Transcarent, the fast-moving company helmed by health tech investor and former Livongo CEO Glen Tullman, today announced $126 million in Series D funding valuing the

May 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.